Marketing-authorisation holder
EMD Serono, Inc.
23 medicines in 1 country, as authorisation holder.
Loading…
Marketing-authorisation holder
23 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
23 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BAVENCIO20mg/ml · Injectable | Avelumab | United States | Marketed | 2017 |
| BAVENCIO20mg/ml · Injectable | Avelumab | United States | Marketed | 2017 |
| CETROTIDE0.25mg base/vial | 3mg base/vial · Powder | Cetrorelix | United States | Marketed | 2000 |
| EUTHYROX0.025mg | 0.05mg | 0.075mg | 0.088mg | 0.112mg | 0.125mg | 0.137mg | 0.15mg | 0.175mg | 0.1mg | 0.2mg | 0.3mg · Tablet | Levothyroxine | United States | Not marketed | 2002 |
| GEREF0.05MG BASE/AMP **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.5MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reason · Injectable | Sermorelin | United States | Not marketed | 1990 |
| GLUCOPHAGE1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 750MG **Federal Register · Tablet | Metformin | United States | Not marketed | 1995 |
| GLUCOPHAGE XR500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, extended release | Metformin | United States | Not marketed | 2000 |
| GONAL-F1,050 iu/vial | 150 iu/vial | 37.5 iu/vial | 450 iu/vial | 75 iu/vial · Injectable | Follitropin alfa/beta | United States | Marketed | 1997 |
| GONAL-F RFF75 iu/vial · Injectable | Follitropin alfa/beta | United States | Marketed | 2004 |
| GONAL-F RFF REDI-JECT150 iu/0.25ml | 300 iu/0.5ml | 450 iu/0.75ml | 900 iu/1.5ml · Injectable | Follitropin alfa/beta | United States | Marketed | 2004 |
| MAVENCLAD10mg · Tablet | Cladribine | United States | Marketed | 2019 |
| OVIDREL0.25mg /0.5ml · Injectable | Choriogonadotropin alfa | United States | Marketed | 2000 |
| OVIDREL0.25mg/vial · Injectable | Choriogonadotropin alfa | United States | Not marketed | 2000 |
| Rebif22mcg/0.5ml · Injection | Interferon beta-1a | United States | Marketed | 2012 |
| Rebif8.8mcg/0.2ml · Injection | Interferon beta-1a | United States | Marketed | 2004 |
| Rebif44mcg/0.5ml · Injection | Interferon beta-1a | United States | Marketed | 2012 |
| Rebif8.8mcg/0.2ml · Injection | Interferon beta-1a | United States | Marketed | 2012 |
| SAIZEN4mg/vial | 5mg/vial | 6mg/vial | 8.8mg/vial · Injectable | Somatropin | United States | Marketed | 1996 |
| SEROPHENE50mg · Tablet | Clomifene | United States | Not marketed | 1982 |
| SEROSTIM4mg/vial | 5mg/vial | 6mg/vial | 8.8mg/vial · Injectable | Somatropin | United States | Marketed | 1996 |
| SEROSTIM LQ6mg/0.5ml (6mg/0.5ml) · Injectable | Somatropin | United States | Not marketed | 1996 |
| TEPMETKO225mg base · Tablet | Tepotinib | United States | Marketed | 2021 |
| ZORBTIVE4mg/vial | 5mg/vial | 6mg/vial | 8.8mg/vial · Injectable | Somatropin | United States | Marketed | 2003 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 23 | 23 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep EMD Serono, Inc.’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callOther companies in the same group.